Welcome to The Visible Embryo

Home- - -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- News Alerts -Contact

Welcome to The Visible Embryo, a comprehensive educational resource on human development from conception to birth.

The Visible Embryo provides visual references for changes in fetal development throughout pregnancy and can be navigated via fetal development or maternal changes.

The National Institutes of Child Health and Human Development awarded Phase I and Phase II Small Business Innovative Research Grants to develop The Visible Embryo. Initally designed to evaluate the internet as a teaching tool for first year medical students, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than ' million visitors each month.


WHO International Clinical Trials Registry Platform
The World Health Organization (WHO) has created a new Web site to help researchers, doctors and patients obtain reliable information on high-quality clinical trials. Now you can go to one website and search all registers to identify clinical trial research underway around the world!



Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

Contact The Visible Embryo

News Alerts Archive

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.
Content protected under a Creative Commons License.

No dirivative works may be made or used for commercial purposes.

Return To Top Of Page
Pregnancy Timeline by SemestersFemale Reproductive SystemFertilizationThe Appearance of SomitesFirst TrimesterSecond TrimesterThird TrimesterFetal liver is producing blood cellsHead may position into pelvisBrain convolutions beginFull TermWhite fat begins to be madeWhite fat begins to be madeHead may position into pelvisImmune system beginningImmune system beginningPeriod of rapid brain growthBrain convolutions beginLungs begin to produce surfactantSensory brain waves begin to activateSensory brain waves begin to activateInner Ear Bones HardenBone marrow starts making blood cellsBone marrow starts making blood cellsBrown fat surrounds lymphatic systemFetal sexual organs visibleFinger and toe prints appearFinger and toe prints appearHeartbeat can be detectedHeartbeat can be detectedBasic Brain Structure in PlaceThe Appearance of SomitesFirst Detectable Brain WavesA Four Chambered HeartBeginning Cerebral HemispheresEnd of Embryonic PeriodEnd of Embryonic PeriodFirst Thin Layer of Skin AppearsThird TrimesterDevelopmental Timeline
Click weeks 0 - 40 and follow fetal growth
Search artcles published since 2007

July 4, 2012--------News Archive Return to: News Alerts


Anticoagulant treatments are currently used for many women with aPLs,
but identifying who to treat is not clear and this treatment is often ineffective.

WHO Child Growth Charts

       

Study On Pregnancy Complications, Overturns Common Belief

Lupus anticoagulant antibodies interfere with blood vessel function putting women at risk for pregnancy complications or loss, but other antibodies in the same family do not. Why?

The researchers say that many doctors may be unnecessarily treating some pregnant women who have antiphospholipid antibodies (aPLs) with anticoagulants, such as expensive heparin injections, which can cause bleeding and bone loss.

The multicenter study appears in the July 2012 issue of the journal Arthritis & Rheumatism.

"This paper identifies people who are at risk for pregnancy loss and, more importantly, those who are not at risk and who therefore do not need to be treated," said Michael Lockshin, M.D., director, Barbara Volcker Center for Women and Rheumatic Disease, and co-director, Mary Kirkland Center for Lupus Research at Hospital for Special Surgery (HSS), New York City, and lead author of the study.


Antiphospholipid antibodies interfere with phospholipids,
a type of fat found in all living cells and cell membranes,
including blood cells and the lining of blood vessels.


Patients with these antibodies are at risk for blood clots, stroke, and pregnancy complications, but some patients with these antibodies can be completely healthy.


"Phospholipids are highly exposed in the placenta, and as a result antiphospholipid antibodies concentrate there," said Jane Salmon, M.D., the study's senior author and Collette Kean Research Chair and co-director, Mary Kirkland Center for Lupus Research at HSS.

"When antibodies are deposited in a person's tissues, inflammation is initiated leading to organ damage." And this is a mechanism for pregnancy complications.

Women who have recurrent pregnancy loss are commonly tested for the presence of aPLs, and up to 15% are positive. Most patients who test positive are treated with anticoagulants.


Currently, there are no standards regarding which aPLs doctors test for to assess risk (there are three main ones) and interlaboratory consistency of results is poor.


These latest results are from the first clinical research publication of the PROMISSE study. PROMISSE is an ongoing multicenter, clinical trial comparing the pregnancies of women with aPL, lupus, aPL and lupus combined, and healthy controls. Between 20% and 35% of patients with lupus and aPL have pregnancy complications and the study is attempting to identify which patients are at risk.

"The identification of biomarkers of patients at high risk will allow us to select a subset of patients for an interventional trial," said Dr. Salmon, the principal investigator of PROMISSE.

The current analysis was focused on 144 patients who had aPLs, 28 of whom had adverse pregnancy outcomes. A control group, 159 healthy pregnant women, was tested parallel to the group with aPLs. Controls were selected among women with no known illness, no prior fetal loss, no more than one miscarriage and at least one successful pregnancy.

The study examined the association between adverse pregnancy outcome and the presence of three different aPLs:

(1) lupus anticoagulant [LAC]
(2) anticardiolipin antibody [aCL]
(3) 2 glycoprotein I

An adverse pregnancy outcome was defined as: unexplained fetal death after 12 weeks, neonatal death prior to discharge that was associated with complications of prematurity, preterm delivery prior to 34 weeks because of gestational hypertension, preeclampsia or placental insufficiency, and birthing a child that was small for its gestational age.

The researchers found that the lupus anticoagulant (LAC) was the strongest predictor of an adverse pregnancy outcome; 39% of patients with LAC had an adverse outcome compared to 3% who did not have LAC (P<0.0001). Only 8% of women with aCL, but not LAC, suffered an adverse outcome. Other aPLs did not increase risk.


"Lupus anticoagulant (LAC) is the most important predictor of risk and that a high titer of anticardiolipin antibodies (aCL) alone don't provide substantial risk."
Dr. Salmon


Dr. Salmon noted that prior to the PROMISSE study, many physicians considered aCL as a potent predictor of risk.

Anticoagulant treatments are currently used for many women with antiphospholipid antibodies (aPLs), but identifying who to treat is not clear and treatment is often ineffective.

Dr. Salmon: "Although many patients with aPLs are treated with heparin, pregnancy outcomes are still disappointing. We need better therapies. This study will allow us to identify subsets of patients with the highest risk in whom to test new approaches and new drugs."

Dr. Salmon's studies in mice with aPL have shown that blocking inflammatory pathways can prevent miscarriages, growth restriction and preeclampsia. Further studies on samples from PROMISSE patients, followed by interventional trials will hopefully shed light on whether this therapeutic approach will be effective in pregnant women with aPLs and/or lupus.

PROMISSE involves over 700 patients from nine centers in North America, and is funded by the National Institute of Arthritis, Musculoskeletal and Skin Diseases of the National Institutes of Health. A strength of PROMISSE is that all aPL tests were sent to core laboratories, eliminating interlaboratory variability.

Other investigators also involved in the study include Lisa Sammaritano, M.D., from Hospital for Special Surgery; D. Ware Branch, M.D., University of Utah Sciences Center and Intermountain Heatlhcare, Salt Lake City; Jill Buyon, M.D., New York University School of Medicine; Carl A. Laskin, M.D., University of Toronto, Toronto; Joan Merrill, M.D., Oklahoma Medical Research Foundation and the University of Oklahoma Sciences Center; Michelle Petri, M.D., MPH, Johns Hopkins University School of Medicine; T Flint Porter, M.D., University of Utah Health Sciences Center and Intermountain Healthcare, Salt Lake City; and Mary Stephenson, M.D., University of Chicago.

Founded in 1863, Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is nationally ranked No. 1 in orthopedics, No. 2 in rheumatology, No. 19 in neurology, and No. 16 in geriatrics by U.S.News & World Report (2011-12), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center three consecutive times. HSS has one of the lowest infection rates in the country. From 2007 to 2011, HSS has been a recipient of the HealthGrades Joint Replacement Excellence Award. HSS is a member of the NewYork-Presbyterian Healthcare System and an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.

Original article: http://www.eurekalert.org/pub_releases/2012-07/hfss-ssl070312.php